06 January 1997
Ann Transplant 1997; 2(1): 5-11 :: ID: 497117
Clinical heart transplantation using human cadaver organs remains the most effective therapy for end-stage heart disease; however, the severe shortage of organs has led to alternative strategies utilizing non-human organs (xenografts). In human allotransplantation, the predominant antigenic differences between donor and recipient are confined to the major histocompatibility and blood group antigens. In contrast, a xenograft is able to express a variety of antigens, in addition to the major histocompatibility and blood group antigens, which are not expressed by human cells and can elicit anti-xenograft immunity in human recipients.
Keywords: discordant xenotransplantation, anti-Galantibodies, delayed rejection, T lymphocytes, transgenic animals
Most Viewed Current Articles
26 Jan 2022 : Review articleRecurrence of Hepatocellular Carcinoma After Liver Transplantation: Risk Factors and Predictive Models
Ann Transplant 2022; 27:e934924
24 Aug 2021 : Review articleNormothermic Machine Perfusion (NMP) of the Liver – Current Status and Future Perspectives
Ann Transplant 2021; 26:e931664
29 Dec 2021 : Original articleEfficacy and Safety of Tacrolimus-Based Maintenance Regimens in De Novo Kidney Transplant Recipients: A Sys...
Ann Transplant 2021; 26:e933588